Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

Testosterone: Functions and Regulation

Testosterone: Functions and Regulation

The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

The Bidirectional Association Between MASLD and Male Hypogonadism: An Updated Meta-Analysis.

Andrology·2026

Same author

No racial disparities in prostate cancer-specific mortality after biochemical recurrence following radical prostatectomy or radiation therapy.

Prostate cancer and prostatic diseases·2026

Same author

External validation of the European association of urology biochemical recurrence risk groups to predict mortality after radical prostatectomy or radiation therapy in a North American cohort.

BJUI compass·2026

Same author

Rethinking Onconephrology: A Nephro-Nutritional Integrated Approach in Patients with Chronic Kidney Disease and Urological Malignancies.

Nutrients·2026

Same author

A preoperative Artificial Intelligence model to estimate cancer-specific mortality in nonmetastatic kidney cancer patients.

Nature communications·2026

Same author

Single Epididymis Metastasis 12 Years After Radical Prostatectomy: A Case Report and Literature Review.

Case reports in urology·2026

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Testosterone Therapy After Radical Prostatectomy: Insights From a Systematic Review and Meta-Analysis.

Giovanni Corona¹, Luís Afonso Morgado^2,3, Paolo Capogrosso⁴

¹Endocrinology and Metabolic Disease Unit, Specialist Medicine Department, AUSL Romagna, Forlì-Cesena, Italy.

|June 23, 2026

Summary

This summary is machine-generated.

Testosterone therapy (TTh) in men treated with TTh after prostatectomy for prostate cancer (PCa) showed a low risk of biochemical recurrence (BCR). Further research is needed to confirm safety and efficacy in this population.

Keywords:

prostate cancer radical prostatectomy testosterone replacement therapy testosterone therapy

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Related Experiment Videos

Last Updated: Jun 24, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Area of Science:

Urology
Endocrinology
Oncology

Background:

The safety of testosterone therapy (TTh) in men with a history of prostate cancer (PCa) post-prostatectomy (RP) is debated.
Previous studies often included heterogeneous patient groups, limiting clear interpretations.

Purpose of the Study:

To systematically review and meta-analyze the risk of biochemical recurrence (BCR) in hypogonadal men undergoing TTh after RP for PCa.

Main Methods:

A systematic literature search was performed following PRISMA and MOOSE guidelines.
Seven retrospective studies with 398 patients were included in the meta-analysis.
Random-effects models and meta-regression analyzed BCR rates and related clinical variables.

Main Results:

The pooled BCR rate in patients receiving TTh was 3.5% (95% CI: 1.5-8.5).
No significant associations were found between BCR and age, Gleason score, or follow-up duration.
TTh was linked to a lower BCR risk compared to controls and suggested improvements in sexual function and quality of life.

Conclusions:

TTh after RP in hypogonadal men with PCa appears to have a limited risk of BCR.
Definitive conclusions are limited by the absence of randomized controlled trials and incomplete data.
Larger prospective studies are necessary to confirm findings and establish long-term safety.